PolyPid (PYPD) Long-Term Deferred Tax (2019 - 2025)
PolyPid (PYPD) posted Long-Term Deferred Tax of $59.3 million for Q4 2025, up 29.54% sequentially from $45.8 million in Q4 2024, and up 29.54% YoY from $45.8 million in Q4 2024.
PolyPid (PYPD) Long-Term Deferred Tax (2019 - 2025) Analysis & Trends
PolyPid has reported Long-Term Deferred Tax for 6 years, with the latest figure at $59.3 million in Q4 2025.
- Quarterly Long-Term Deferred Tax rose 29.54% year-over-year to $59.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $59.3 million (up 29.54% YoY) and the FY2025 annual result came in at $59.3 million, up 29.54% from the prior year.
- Long-Term Deferred Tax grew to $59.3 million in Q4 2025 per PYPD's latest filing, from $45.8 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $59.3 million in Q4 2025 and troughed at $31.3 million in Q4 2021.
- A 4-year average of $42.8 million and a median of $40.4 million in 2022 frame the typical range for Long-Term Deferred Tax.
- The sharpest annual moves came in 2022 and 2025: Long-Term Deferred Tax rose 11.81% in 2022, then rose 29.54% in 2025.
- Over 4 years, Long-Term Deferred Tax stood at $31.3 million in 2021, then increased by 11.81% to $35.0 million in 2022, then jumped by 30.78% to $45.8 million in 2024, then grew by 29.54% to $59.3 million in 2025.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $59.3 million, $45.8 million, and $35.0 million for Q4 2025, Q4 2024, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | PolyPid | 113.86 Mn | 107.09 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 59.27 Mn |
| Dec 31, 2024 | 45.75 Mn |
| Dec 31, 2022 | 34.98 Mn |
| Dec 31, 2021 | 31.29 Mn |
| Dec 31, 2020 | 26.96 Mn |
| Dec 31, 2019 | 17.78 Mn |